|
Press Releases |
|
|
|
Wednesday, May 15, 2024 |
|
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
Monday, May 13, 2024 |
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures |
Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) Fycompa (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. more info >> |
|
Thursday, April 18, 2024 |
|
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) |
Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology. more info >> |
|
Wednesday, April 17, 2024 |
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan |
Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan. more info >> |
|
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は本日、日本において自社創製の抗てんかん剤「フィコンパ(R)」(一般名:ペランパネル水和物、海外製品名:「Fycompa(R)」)の点滴静注用製剤について新発売したことをお知らせします。 more info >> |
|
Wednesday, April 3, 2024 |
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
Monday, April 1, 2024 |
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
Friday, March 29, 2024 |
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd. more info >> |
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture |
Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture. more info >> |
|
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 |
Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Indonesia calls for global action on sustainable water management at the 10th World Water Forum
May 21, 2024 20:00 HKT/SGT
|
|
|
Tommy Chong Lights World-Record 23-Pound Blunt 'Up in Smoke' in Bel Air, California
May 21, 2024 19:00 HKT/SGT
|
|
|
25th Edition Manufacturing IT Summit: Shaping the Future of Manufacturing Technology
May 21, 2024 17:59: JST
|
|
|
25th Edition Manufacturing IT Summit: Shaping the Future of Manufacturing Technology
May 21, 2024 16:59 HKT/SGT
|
|
|
三菱重工、防衛省向け3,900トン型護衛艦「やはぎ」を長崎にて引渡し
May 21, 2024 16:16: JST
|
|
|
Naehas and Itea P2B AB Partner to Bring Enhanced Value to Financial Services Billing and Disclosures
May 21, 2024 15:30 HKT/SGT
|
|
|
內地乘客可網上下單預約大巴車直達港澳
May 21, 2024 12:43 HKT/SGT
|
|
|
The cybersecurity capital of Philippines, PhilSec now an essential choice for critical infrastructure
May 21, 2024 12:20 HKT/SGT
|
|
|
Spritzer's 'Plastic Reimagined' inspires exciting ideas whilst giving new life and uses to recycled plastic
May 21, 2024 12:00 HKT/SGT
|
|
|
富士通など、先端AI技術を活用したザトウクジラの来遊状況把握と観光振興への活用可能性の検証の取り組み強化について
May 21, 2024 12:00: JST
|
|
|
Alta Partners with TRIREC to Unlock Opportunities in Impact Investing for Third Climate-Focused Fund
May 21, 2024 11:00 HKT/SGT
|
|
|
Fujitsu and Mizuho leverage AI to track trends in humpback whale migration and promote sustainable tourism for Hachijo Island
May 21, 2024 11:51 JST
|
|
|
Hitachi High-Tech and Hitachi have started collaborating on digital transformation of materials development with ITRI, contributing to improvements of Taiwan's industrial standards
May 21, 2024 11:01 JST
|
|
|
Mahkota Medical Centre: Promoting Women Empowerment
May 21, 2024 08:00 HKT/SGT
|
|
|
InsureTech Connect Asia: Asia's Largest Insurance Ecosystem Conference
May 20, 2024 18:08 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|